scholarly journals Assessment of Candidal carriage in patients with Type II Diabetes Mellitus

2015 ◽  
Vol 5 (9) ◽  
pp. 733-738 ◽  
Author(s):  
RS Lamichhane ◽  
K Boaz ◽  
S Natarajan ◽  
M Shrestha
Keyword(s):  
Diabetes Mellitus ◽  
Fungal Infections ◽  
Surrogate Marker ◽  
Salivary Flow ◽  
Type Ii Diabetes Mellitus ◽  
Serum Glucose ◽  
Denture Stomatitis ◽  
Oral Rinse ◽  
Increased Risk ◽  
Patients With Diabetes

Background: It is generally acknowledged that patients with diabetes mellitus are more susceptible to fungal infections, particularly with Candida albicans. Oral infection by Candida can result in a number of clinical lesions, including median rhomboid glossitis (central papillary atrophy), denture stomatitis, squamous cell carcinoma, Radiation therapy, immunocompromised status, etc. Different studies have shown that patients with diabetes mellitus have increased frequency of oral candidal carriage and increased risk of candidiasis, which is related to poor metabolic control, neutrophil dysfunction, reduced salivary flow, high glucose concentration in blood and saliva and in medications.Materials and Methods: Subjects of both the groups were given 10 ml of sterile normal saline and asked to rinse the mouth for one minute. The subjects were then asked to return the oral rinse in a sterile clean, broad-mouthed container which was capped, labelled and taken to the laboratory. The samples were then inoculated onto the culture medium (Sabouraud’s dextrose agar with Chloramphenicol) with minimal delay (within 6-8 hours of collection of oral rinse). Candidal colonies were counted and compared with non-diabetics.Results: Statistically significant increase in colony forming units (p=0.0324) were obtainedin patients with diabetes mellitus.Conclusion: The results indicate significant increase in colonization and carriage of candida in the oral cavity among diabetics when compared with non-diabetics. However, further research using larger samples is required which may lend credibility to the suggestion of increased candidal CFUs in diabetics serving as a surrogate marker of serum glucose levels.Journal of Pathology of Nepal (2015) Vol. 5, 733-738

scholarly journals Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Caroline Bartolo ◽  
Victoria Hall ◽  
N. Deborah Friedman ◽  
Chloe Lanyon ◽  
Andrew Fuller ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Fungal Infections ◽  
Case Reports ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Urogenital Tract ◽  
Hypoglycemic Agents ◽  
Drug Induced ◽  
First Case ◽  
Increased Risk

Abstract Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor. Case presentations Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with Candida albicans balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with Candida glabrata candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased. Conclusions Despite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.

CASE SERIES: A SPECTRUM OF FUNGAL INFECTIONS IN COVID-19

2021 ◽  
pp. 29-30
Author(s):  
Venkatesh B. C. ◽  
Rajendra Rao K. M. ◽  
K. N. Mohan Rao
Keyword(s):  
Diabetes Mellitus ◽  
Fungal Infections ◽  
Virus Disease ◽  
Case Series ◽  
Health Crisis ◽  
Major Health ◽  
Corona Virus ◽  
Patients With Diabetes ◽  
Causative Agents

Corona virus Disease 2019 (COVID-19) pandemic is causing a major health crisis across the globe. With the increasing number of fungal infections associated with COVID-19 being reported, it is imperative to understand the spectrum of such infections. Most documented cases have been reported in patients with diabetes mellitus or treatment with immunomodulators. The most common causative agents are Aspergillus, Candida or Mucorales. This series aims to portray the spectrum of fungal infections associated with COVID-19.

scholarly journals Effect of Antidiabetic Treatment on Bone

2019 ◽  
pp. S107-S120 ◽  
Author(s):  
J. JACKULIAK ◽  
M. KUŽMA ◽  
J. PAYER
Keyword(s):  
Diabetes Mellitus ◽  
Bone Fractures ◽  
Negative Impact ◽  
Osteoporotic Fractures ◽  
Antidiabetic Drugs ◽  
Mineral Density ◽  
Skeletal Health ◽  
Antidiabetic Treatment ◽  
Increased Risk ◽  
Patients With Diabetes

Patients with diabetes mellitus are at an increased risk of bone fractures. Several groups of effective antidiabetic drugs are available, which are very often given in combination. The effects of these medications on bone metabolism and fracture risk must not be neglected. Commonly used antidiabetic drugs might have a positive, neutral or negative impact on skeletal health. Increased risk of fracture has been identified with use of thiazolidinediones, most definitively in women. Also treatment with sulfonylureas can have adverse effects on bone. One consequence of these findings has been greater attention to fracture outcomes in trails of new diabetes medication (incretins and SGLT-2 inhibitors). The effect of insulin on bone is discussed and the risk of fractures in patients using insulin seems to be unrelated to insulin as itself. The aim of the review is to summarize effects of antidiabetic treatment on bone – bone mineral density, fractures and bone turnover markers. The authors also try to recommend a strategy how to treat patients with diabetes mellitus regarding the risk of osteoporotic fractures. In this review the problem of how to treat osteoporosis in patient with diabetes is also discussed.

scholarly journals Pola Kehidupan yang Baik bagi Penderita Diabetes Melitus

2019 ◽  
Author(s):  
aura widad al addawiyah hamzah
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Blood Sugar ◽  
Type Ii Diabetes Mellitus ◽  
Contributing Factors ◽  
Food Attitudes ◽  
Patients With Diabetes ◽  
Sugar Levels ◽  
The Relationship ◽  
Diabetes Melitus

Diabetes mellitus is a chronic metabolic disorder characterized by an increase in blood glucose (hyperglycemia). Physical activity has an impact on insulin action in people at risk for diabetes mellitus.Lack of activity is one of the contributing factors that causes insulin resistance in type II diabetes mellitus and diet is the behavior of humans or a group of humans in meeting their dietary needs which include food attitudes, beliefs and choices. The purpose of this study was to analyze the relationship between patterns of physical activity and diet with blood sugar levels in patients with diabetes melitustipe II. The research method used is a qualitative method. The results of the study showed that there was a relationship between patterns of physical activity and diet with blood sugar levels. Conclusions there is a relationship between patterns of physical activity and diet with blood sugar levels in patients with diabetes melitustipe II

Adenosine deaminase activity and zinc levels in the serum of patients with diabetes mellitus

2016 ◽  
Vol 41 (6) ◽  
Author(s):  
Rana Turkal ◽  
Göksel Bahadır ◽  
Yasemin Erdoğan Döventaş ◽  
Goncagül Haklar ◽  
Önder Şirikçi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Adenosine Deaminase ◽  
Type Ii Diabetes Mellitus ◽  
Diabetic Patients ◽  
Type I ◽  
Adenosine Deaminase Activity ◽  
Patients With Diabetes ◽  
Patient Groups ◽  
Zinc Levels ◽  
Two Parameters

AbstractObjective:Adenosine deaminase (ADA) specifically catalyzes the deamination of adenosine which has been proved to play an important role in modulation of insulin action on glucose metabolism. Zinc is an essential micronutrient that is directly involved in the physiology of insulin and may be an important agent to activate the ADA. We aimed to evaluate serum ADA activity, zinc levels and the relationship between these two parameters in diabetes mellitus.Methods:We investigated serum ADA activity and zinc levels in type I (n = 100) and type II diabetes mellitus patients (n = 151).Results:ADA activities of diabetic patients were significantly elevated, whereas zinc levels were significantly lower than those of healthy controls (p < 0.001). Compared with the well-controlled diabetic patient groups (HbAConclusion:Elevated ADA activity in diabetic patients with poor glycemic control may be a useful marker for therapy modulation.

Abstract 12096: Temporal Trends in Ischemic Stroke and Anticoagulation Therapy Among Medicare Beneficiaries Having Non-Valvular Atrial Fibrillation With and Without Diabetes Mellitus, 1992-2010

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Gautam R Shroff ◽  
Craig A Solid ◽  
Charles A Herzog
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Temporal Trends ◽  
Significant Proportion ◽  
Anticoagulation Therapy ◽  
Medicare Beneficiaries ◽  
Similar Reduction ◽  
Increased Risk ◽  
Patients With Diabetes

Background: Patients with diabetes mellitus (DM) and non valvular atrial fibrillation (AF) are at increased risk of ischemic stroke; but evidence regarding ischemic stroke and warfarin use in the literature is limited. We evaluated temporal trends in ischemic stroke and warfarin use among the US Medicare population with and without DM. Methods: One-year cohorts of patients with Medicare as primary payer, 1992-2010, were created using the Medicare 5% sample. ICD-9-CM codes were used to identify AF, ischemic and hemorrhagic stroke and comorbidities; ≤3 consecutive prothrombin-time claims were used to identify warfarin use. Results: Demographic characteristics between 1992 (n=40255) and 2010 (n=80314) respectively were (proportions): age 65-74 years (37%, 32%); age ≤ 85 years (20%, 25%); white (94%, 93%); hypertension (46%, 80%); DM (20%, 32%), chronic kidney disease (5%, 18%). Ischemic stroke rates among Medicare AF patients with DM decreased by 71% (1992, 2010) from 65 to 19 /1000 patient-years; warfarin utilization increased from 28% to 62% respectively (Figure 1A). Among Medicare AF patients without DM, ischemic stroke rates decreased by 68% from 44 to 14/ 1000 patient-years; warfarin use increased 26% to 59% respectively (Figure 1B). About 38% Medicare AF pts with DM did not receive anticoagulation in 2010. Conclusion: Medicare patients with and without DM had a similar reduction in ischemic stroke rates; and similar increase in warfarin utilization over the study period. A significant proportion of Medicare pts with DM did not receive anticoagulation with warfarin for AF in 2010; this population deserves future attention.

Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus

2002 ◽  
Vol 11 (6) ◽  
pp. 504-519 ◽  
Author(s):  
Deborah Chyun ◽  
Viola Vaccarino ◽  
Jaime Murillo ◽  
Lawrence H. Young ◽  
Harlan M. Krumholz
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Heart Failure ◽  
Elderly Patients ◽  
Ventricular Function ◽  
Clinical Findings ◽  
Comorbid Conditions ◽  
Recurrent Myocardial Infarction ◽  
Increased Risk ◽  
Patients With Diabetes

• Objective To examine the association between (1) comorbid conditions related to diabetes mellitus, clinical findings on arrival at the hospital, and characteristics of the myocardial infarction and (2) risk of heart failure, recurrent myocardial infarction, and mortality in the year after myocardial infarction in elderly 30-day survivors of myocardial infarction who had non–insulin- or insulin-treated diabetes. • Methods Medical records for June 1, 1992, through February 28, 1993, of Medicare beneficiaries (n = 1698), 65 years or older, hospitalized for acute myocardial infarction in Connecticut were reviewed by trained abstractors. • Results One year after myocardial infarction, elderly patients with non–insulin- and insulin-treated diabetes mellitus had significantly greater risk for readmission for heart failure and recurrent myocardial infarction than did patients without diabetes mellitus, and risk was greater in patients treated with insulin than in patients not treated with insulin. Diabetes mellitus, comorbid conditions related to diabetes mellitus, clinical findings on arrival, and characteristics of the myocardial infarction, specifically measures of ventricular function, were important predictors of these outcomes. Mortality was greater in patients not treated with insulin than in patients treated with insulin; the increased risk was mostly due to comorbid conditions related to diabetes mellitus and poorer ventricular function. • Conclusions Risk of heart failure, recurrent myocardial infarction, and mortality is elevated in elderly patients who have non–insulin- or insulin-treated diabetes mellitus. Comorbid conditions related to diabetes mellitus and ventricular function at the time of the index myocardial infarction are important contributors to poorer outcomes in patients with diabetes mellitus.

scholarly journals The Risk of Gastrointestinal Hemorrhage in Low-Dose Aspirin Users with Diabetes Mellitus: Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Yashuo Wang ◽  
Wei Wang ◽  
Bin Wang ◽  
Yunyang Wang
Keyword(s):  
Diabetes Mellitus ◽  
Low Dose ◽  
Meta Analysis ◽  
Quality Data ◽  
Cochrane Library ◽  
Knowledge Infrastructure ◽  
Dose Aspirin ◽  
Increased Risk ◽  
Low Dose Aspirin ◽  
Patients With Diabetes

Background. Our aim was to assess the risk of gastrointestinal (GI) hemorrhage associated with diabetes among patients taking low-dose aspirin (≤325 mg/day). Methods. A systematic search was conducted for publication in English and Chinese using term equivalents for “GI hemorrhage”, “aspirin”, and “diabetes mellitus” up till April 2020. Electronic databases include PUBMED, EMBASE, Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database. Two independent authors searched databases and reviewed abstracts for comprehensive studies keeping adequate study quality. Data of weighted odds ratios were statistically evaluated and potential bias was checked. Results. Among 446 publications, eight case-control researches, including 1601 patients, were deemed for this meta-analysis. Patients with diabetes were associated with a higher risk of GI hemorrhage than patients without diabetes: the summary ORs were 3.10 (95% CI, 2.35–4.09). The heterogeneity of the reports was not significant (Chi2=3.39, P=0.85; I2=0%). Conclusion. The meta-analysis showed that aspirin users with diabetes were more likely to have GI hemorrhage. Hence, when treating diabetics with aspirin, the increased risk of GI bleeding should be taken in consideration.

scholarly journals Association of Food Pharmacy Participation with Type II Diabetes Mellitus Risk Factors

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 292-292
Author(s):  
Breanne Vinogradoff ◽  
Giselle Pereira Pignotti ◽  
Marcelle Dougan ◽  
John Gieng
Keyword(s):  
Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Participation Rate ◽  
Safety Net ◽  
Type Ii Diabetes Mellitus ◽  
Clinical Markers ◽  
Funding Sources ◽  
Increased Risk ◽  
High Participation ◽  
Diabetes Mellitus Risk

Abstract Objectives Food insecurity poses a public health threat in a number of concerning ways, including increased risk of Type 2 Diabetes Mellitus (T2DM). A number of safety-net resource sites in the US are working to address this complex relationship through the disbursal of medically tailored food to clients with T2DM, sometimes referred to as a “food pharmacy”. Our study aimed to determine if participation by food insecure individuals in a food pharmacy affected clinical markers of T2DM status or risk, namely glycated hemoglobin (HbA1c), fasting blood glucose (FBG), or body mass index (BMI). Methods We conducted a retrospective study of data from a food pharmacy run by a safety-net healthcare clinic in California. Data from January 2016 through May 2019 were analyzed. Patients with T2DM were referred to the food pharmacy by clinic physicians. After referral, patients could pick up boxes of diabetes appropriate food (contents were determined by program staff and varied based on food availability) once a week. Results from participant's successive biomedical tests were recorded by clinic staff. Participants with a baseline measurement of HbA1c, FBG, or BMI within ±11 days of food pharmacy referral and at least one subsequent measurement of the same variable qualified for inclusion (n = 161). Participation rate was defined as the proportion of food pickup opportunities attended by each individual. Spearman correlation analysis, t-tests, and analyses of variance were conducted to determine the association between program participation on HbA1c, FBG, and BMI. Results At 24 months, increased food pharmacy participation correlated with a reduction in BMI (r = –0.39, P = 0.03, n = 29). As compared with those who participated below the median rate, the “high participation” group had a lower mean BMI at 24 months (34.6 ± 9.1 vs 29.1 ± 4.9 kg/m2, P = 0.05). Mean HbA1c was lower at 18 months as compared to baseline (9.1 ± 2.3 vs 8.2 ± 1.8%, P = 0.04). However, HbA1c and FBG were not correlated with participation rate. Conclusions This study found higher food pharmacy participation rates are associated with reductions in BMI, but not HbA1c or FBG. Food pharmacies may need to reevaluate their treatment model if they are to effectively target T2DM in food insecure individuals. Funding Sources None.

Sign in / Sign up

Export Citation Format

Share Document